175 related articles for article (PubMed ID: 27438154)
21. A Novel Invasive-Related Biomarker in Three Subtypes of Nonfunctioning Pituitary Adenomas.
Chen Y; Chuan HL; Yu SY; Li CZ; Wu ZB; Li GL; Zhang YZ
World Neurosurg; 2017 Apr; 100():514-521. PubMed ID: 28093347
[TBL] [Abstract][Full Text] [Related]
22. Pituitary adenomas secreting large amounts of prolactin may give false low values in immunoradiometric assays. The hook effect.
Petakov MS; Damjanović SS; Nikolić-Durović MM; Dragojlović ZL; Obradović S; Gligorović MS; Simić MZ; Popović VP
J Endocrinol Invest; 1998 Mar; 21(3):184-8. PubMed ID: 9591215
[TBL] [Abstract][Full Text] [Related]
23. Matrix metalloproteinase-9, a potential biological marker in invasive pituitary adenomas.
Gong J; Zhao Y; Abdel-Fattah R; Amos S; Xiao A; Lopes MB; Hussaini IM; Laws ER
Pituitary; 2008; 11(1):37-48. PubMed ID: 17768685
[TBL] [Abstract][Full Text] [Related]
24. Expression of p53, Ki-67 and c-erb B2 in growth hormone-and/or prolactin-secreting pituitary adenomas.
Botelho CH; Magalhães AV; Mello PA; Schmitt FC; Casulari LA
Arq Neuropsiquiatr; 2006 Mar; 64(1):60-6. PubMed ID: 16622555
[TBL] [Abstract][Full Text] [Related]
25. [Spheroidal amyloid deposits in prolactin-secreting pituitary adenomas: report of a case].
Yang YL; Liu B; Qian Z; Ha YD; Su QJ
Zhonghua Bing Li Xue Za Zhi; 2009 Nov; 38(11):776-7. PubMed ID: 20079021
[No Abstract] [Full Text] [Related]
26. Galectin-3 and Estrogen Receptor Alpha as Prognostic Markers in Prolactinoma: Preliminary Results From a Pilot Study.
Bima C; Chiloiro S; Giampietro A; Gessi M; Mattogno PP; Lauretti L; Anile C; Rindi G; Pontecorvi A; De Marinis L; Bianchi A
Front Endocrinol (Lausanne); 2021; 12():684055. PubMed ID: 34322092
[TBL] [Abstract][Full Text] [Related]
27. Estrogen receptors in human pituitary tumors.
Burdman JA; Pauni M; Heredia Sereno GM; Bordón AE
Horm Metab Res; 2008 Aug; 40(8):524-7. PubMed ID: 18398784
[TBL] [Abstract][Full Text] [Related]
28. Subclinical adenomas in postmortem pituitaries: classification and correlations to clinical data.
Buurman H; Saeger W
Eur J Endocrinol; 2006 May; 154(5):753-8. PubMed ID: 16645024
[TBL] [Abstract][Full Text] [Related]
29. Pancreastatin secretion by pituitary adenomas and regulation of chromogranin B mRNA expression.
Jin L; Scheithauer BW; Young WF; Davis DH; Klee GG; Lloyd RV
Am J Pathol; 1996 Jun; 148(6):2057-66. PubMed ID: 8669489
[TBL] [Abstract][Full Text] [Related]
30. Resveratrol inhibited GH3 cell growth and decreased prolactin level via estrogen receptors.
Wang C; Hu ZQ; Chu M; Wang Z; Zhang WG; Wang LZ; Li CG; Wang JS
Clin Neurol Neurosurg; 2012 Apr; 114(3):241-8. PubMed ID: 22104698
[TBL] [Abstract][Full Text] [Related]
31. Pituitary tumor transforming gene and insulin-like growth factor 1 receptor expression and immunohistochemical measurement of Ki-67 as potential prognostic markers of pituitary tumors aggressiveness.
Sánchez-Tejada L; Sánchez-Ortiga R; Moreno-Pérez O; Montañana CF; Niveiro M; Tritos NA; Alfonso AM
Endocrinol Nutr; 2013; 60(7):358-67. PubMed ID: 23416216
[TBL] [Abstract][Full Text] [Related]
32. Loss of 15-hydroxyprostaglandin dehydrogenase indicates a tumor suppressor role in pituitary adenomas.
Bai JW; Wang Z; Gui SB; Zhang YZ
Oncol Rep; 2012 Aug; 28(2):714-20. PubMed ID: 22580984
[TBL] [Abstract][Full Text] [Related]
33. Expression of MMP14 in invasive pituitary adenomas: relationship to invasion and angiogenesis.
Hui P; Xu X; Xu L; Hui G; Wu S; Lan Q
Int J Clin Exp Pathol; 2015; 8(4):3556-67. PubMed ID: 26097538
[TBL] [Abstract][Full Text] [Related]
34. Insights into the clinical value of cyclin-dependent kinase 5 in glioma: a retrospective study.
Yushan R; Wenjie C; Suning H; Yiwu D; Tengfei Z; Madushi WM; Feifei L; Changwen Z; Xin W; Roodrajeetsing G; Zuyun L; Gang C
World J Surg Oncol; 2015 Jul; 13():223. PubMed ID: 26205145
[TBL] [Abstract][Full Text] [Related]
35. Expression of phosphorylated p27(Kip1) protein and Jun activation domain-binding protein 1 in human pituitary tumors.
Korbonits M; Chahal HS; Kaltsas G; Jordan S; Urmanova Y; Khalimova Z; Harris PE; Farrell WE; Claret FX; Grossman AB
J Clin Endocrinol Metab; 2002 Jun; 87(6):2635-43. PubMed ID: 12050228
[TBL] [Abstract][Full Text] [Related]
36. Carcinomas of the pituitary: definition and review of the literature.
Lübke D; Saeger W
Gen Diagn Pathol; 1995 Oct; 141(2):81-92. PubMed ID: 8548598
[TBL] [Abstract][Full Text] [Related]
37. ALK7 expression in prolactinoma is associated with reduced prolactin and increased proliferation.
Principe M; Chanal M; Karam V; Wierinckx A; Mikaélian I; Gadet R; Auger C; Raverot V; Jouanneau E; Vasiljevic A; Hennino A; Raverot G; Bertolino P
Endocr Relat Cancer; 2018 Sep; 25(9):795-806. PubMed ID: 30012586
[TBL] [Abstract][Full Text] [Related]
38. The prolactin-release inhibitor paeoniflorin suppresses proliferation and induces apoptosis in prolactinoma cells via the mitochondria-dependent pathway.
Wei Y; Zhou X; Ren L; Wang C; Li Y
J Cell Biochem; 2018 Jul; 119(7):5704-5714. PubMed ID: 29388711
[TBL] [Abstract][Full Text] [Related]
39. Histologic and immunohistochemical characterization of spontaneous pituitary adenomas in fourteen cynomolgus macaques (Macaca fascicularis).
Remick AK; Wood CE; Cann JA; Gee MK; Feiste EA; Kock ND; Cline JM
Vet Pathol; 2006 Jul; 43(4):484-93. PubMed ID: 16846990
[TBL] [Abstract][Full Text] [Related]
40. Oncogene-Induced Senescence in Pituitary Adenomas--an Immunohistochemical Study.
Manojlovic-Gacic E; Skender-Gazibara M; Popovic V; Soldatovic I; Boricic N; Raicevic S; Pekic S; Doknic M; Miljic D; Alafuzoff I; Pontén F; Casar-Borota O
Endocr Pathol; 2016 Mar; 27(1):1-11. PubMed ID: 26573928
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
